If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

Governor Greg Abbott joined Chief of the National Guard Bureau and member of the Joint Chiefs of Staff General Steven ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Investors who hold lithium mining firms like Albemarle (ALB) and Lithium Americas (LAC) will enjoy Thursday’s rally. ALB stock gained 7.57% while LAC stock closed at 8.82%. A Chinese miner, Zangge ...

Abbott Labs reported a mixed bag of Q2 2025 earnings, showing impressive growth in some areas and facing headwinds in others. Sales grew by almost 7%, and adjusted EPS saw an 11% increase. Medical ...

Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Abbott Laboratories’ second quarter results echoed Johnson & Johnson’s, with med tech performing the hero’s work with strong growth. Overall, Abbott slightly beat expectations with sales up 6.9% ...

Wall Street calms after Trump backs off Fed threats. S&P 500 futures flat; PepsiCo and TSMC rise on strong earnings. Netflix reports later.

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott, a global healthcare leader, has reported strong results for its second quarter of 2025. According to the company's ...